Possible adverse reactions of bosutinib/bosutinib

Bosutinib/Bosutinib is a targeted drug used to treat chronic myelogenous leukemia (CML). Its main mechanism of action is to prevent the proliferation of cancer cells by inhibiting the activity of BCR-ABL tyrosine kinase. In clinical application, although bosutinib shows good efficacy, it is also accompanied by certain adverse reactions, and these reactions may vary among different groups of people.

According to clinical study data, the most common adverse reactions for patients with newly diagnosed chronic Philadelphia chromosome-positive chronic myeloid leukemia (CP Ph+CML) who are resistant or intolerant to previous treatments include diarrhea, rash, nausea, abdominal pain, vomiting and fatigue. These symptoms usually occur early in treatment and may lessen over time. However, diarrhea is often the most troublesome problem for patients. In severe cases, it may lead to dehydration and electrolyte imbalance, so it requires close monitoring and prompt treatment.

In addition, hepatic dysfunction is also a noteworthy side effect of bosutinib treatment. While patients are taking this drug, liver function tests need to be performed regularly to ensure that the liver is not excessively damaged. Respiratory tract infections, fever and headache are common comorbidities, which may be related to changes in the patient's immune system or the direct impact of drugs.

In pediatric patients, the adverse reactions of bosutinib are similar to those in adults, with diarrhea and abdominal pain being particularly prominent. These symptoms may have an impact on a child's quality of life, so clinicians need to take necessary steps to mitigate these reactions.

In addition to common adverse reactions, other serious adverse events have been reported after bosutinib was marketed, such as thrombotic microangiopathy and Stevens-Johnson syndrome. These rare but serious side effects require physicians to carefully assess patient risks when using bosutinib and respond quickly if symptoms occur.

Reference materials:https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adc84ad5-a04d-4fee-9ba8-91f7abd928e3